NasdaqGS - Nasdaq Real Time Price USD

Cabaletta Bio, Inc. (CABA)

Compare

2.0750

-0.2450

(-10.56%)

At close: January 10 at 4:00:02 PM EST

2.2600

+0.19

+(8.92%)

After hours: January 10 at 7:21:09 PM EST

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures

Key Insights Significantly high institutional ownership implies Cabaletta Bio's stock price is sensitive to their...

Simply Wall St. last month

CABA
-10.56%
Cabaletta Bio to Participate in Upcoming Investor Conferences in December

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December: 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of

GlobeNewswire last month

CABA
-10.56%
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion

GlobeNewswire last month

CABA
-10.56%
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201

GlobeNewswire last month

CABA
-10.56%
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA. A live webcast of the presentation will be avai

GlobeNewswire 2 months ago

CABA
-10.56%
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 2 months ago

CABA
-10.56%
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings

On September 30, 2024, State Street Corp executed a significant transaction by reducing its holdings in Cabaletta Bio Inc (NASDAQ:CABA), a clinical-stage biotechnology company. This move reflects a strategic adjustment in State Street Corp's investment portfolio, despite the trade having a minimal immediate impact on its overall position. State Street Corp, headquartered at One Lincoln Street, Boston, MA, is a prominent investment firm known for its robust investment strategies that focus primarily on long-term value creation.

GuruFocus.com 2 months ago

CABA
-10.56%
STT
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. The presentation

GlobeNewswire 3 months ago

CABA
-10.56%
Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY.

GlobeNewswire 4 months ago

CABA
-10.56%
Several Headwinds Dragged Cabaletta Bio (CABA) in Q2

Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities rose during the second quarter of 2024, with the S&P 500 up 4.28%. Additionally, large-cap growth stocks saw significant gains in the quarter, while smaller-cap, […]

Insider Monkey 4 months ago

CABA
-10.56%
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data from the RESET-Myositis™ and RESET-SLE™ trials as well as initial clinical data from the RESET-SSc™ and RESET-MG™ trials anticipated in 2H24 – – Initial clinical and translational data from each of the first patients in the RESET-Myositis and RESET-SLE trials presented at EULAR in June 2024 – – An

GlobeNewswire 5 months ago

CABA
-10.56%
Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Cabaletta Bio, Inc. (NASDAQ:CABA) stands against the other shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making money […]

Insider Monkey 6 months ago

CABA
-10.56%
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024, at 1:00 p.m. ET. A live webcast of the presentation will

GlobeNewswire 6 months ago

CABA
-10.56%
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients’ specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all

GlobeNewswire 6 months ago

CABA
-10.56%
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY. A live webcast of the

GlobeNewswire 7 months ago

CABA
-10.56%
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 7 months ago

CABA
-10.56%
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be presented at a satellite symposium at the EULAR 2024 Congress in June – – Evaluating CABA-201 without preconditioning by initiation of the RESET-PV™ sub-study within the ongoing DesCAARTes™ trial in pemphigus vulga

GlobeNewswire 7 months ago

CABA
-10.56%
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY. A live webcast of the presentation wi

GlobeNewswire 7 months ago

CABA
-10.56%
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway

Q4 and Full Year 2023 Financial Results Reveal Strategic Advancements in Autoimmune Therapies

GuruFocus.com 9 months ago

CABA
-10.56%
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24 – – RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24 – – Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile derma

GlobeNewswire 9 months ago

CABA
-10.56%

Performance Overview

Return	CABA	S&P 500
YTD	-7.37%	-1.35%
1-Year	-91.33%	+22.51%
3-Year	-40.20%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Several Headwinds Dragged Cabaletta Bio (CABA) in Q2

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Performance Overview